Why FDA’s capitulation of genetic therapy is such a big deal

October 12, 2017, 7:32 PM|
On Thursday, an FDA advisory row gave the immature light for a therapy that could urge the prophesy of people who have a singular genetic commotion called Leber’s inborn amaurosis (LCA). CBS News medical writer Dr. Tara Narula weighs in.

Check Also

Patients are confronting eight month wait for hip operations 

By Fiona Parker for The Daily Mail  In step: Frank Larmer and Allison Cousins Dance teacher …